IL-1α Expression in Pancreatic Ductal Adenocarcinoma Affects the Tumor Cell Migration and Is Regulated by the p38MAPK Signaling Pathway

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Tjomsland, Vegard ^a   Bojmar, Linda ^a   Sandström, Per ^a   Bratthäll, Charlotte ^b   Messmer, Davorka ^c   Spångeus, Anna ^a   Larsson, Marie ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ARTICLE; AUTOCRINE EFFECT; CANCER ASSOCIATED FIBROBLAST; CELL MIGRATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS;

EID: 84881519195     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070874     Document Type: Article

References (34)

1. Li D, Xie K, Wolff R, Abbruzzese JL, (2004) Pancreatic cancer. Lancet 363: 1049-1057.
2. Melisi D, Niu J, Chang Z, Xia Q, Peng B, et al. (2009) Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res 7: 624-633.
3. Korc M, (2007) Pancreatic cancer-associated stroma production. Am J Surg 194: S84-86.
4. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, et al. (2004) Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 57: 630-636.
5. Tjomsland V, Niklasson L, Sandstrom P, Borch K, Druid H, et al. (2011) The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol 2011: 212810.
6. Franco OE, Shaw AK, Strand DW, Hayward SW, (2011) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21: 33-39.
7. Sato N, Maehara N, Goggins M, (2004) Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64: 6950-6956.
8. Somasundaram R, Herlyn D, (2009) Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin Cancer Biol 19: 92-96.
9. Tjomsland V, Spangeus A, Valila J, Sandstrom P, Borch K, et al. (2011) Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 13: 664-675.
10. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D, (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774.
11. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, et al. (2003) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030.
12. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ, (2002) Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 62: 283-289.
13. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, et al. (2001) Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 93: 507-515.
14. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, et al. (1994) Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78: 1039-1049.
15. McDermott EP, O'Neill LA, (2002) Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem 277: 7808-7815.
16. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, et al. (2012) KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21: 105-120.
17. Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, et al. (2000) K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1223-1232.
18. Hruban RH, Goggins M, Parsons J, Kern SE, (2000) Progression model for pancreatic cancer. Clin Cancer Res 6: 2969-2972.
19. Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, et al. (2005) Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 65: 8433-8441.
20. Wagner EF, Nebreda AR, (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
21. Chang L, Karin M, (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
22. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R, (2004) Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736.
23. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, et al. (2002) Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. Embo J 21: 6473-6482.
24. Masui T, Doi R, Mori T, Toyoda E, Koizumi M, et al. (2004) Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 315: 85-92.
25. Mu DQ, Peng YS, Xu QJ, (2004) Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 10: 471-475.
26. Tabata T, Fujimori T, Maeda S, Yamamoto M, Saitoh Y, (1993) The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol 14: 237-244.
27. Kim ST, Lim do H, Jang KT, Lim T, Lee J, et al. (2011) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10: 1993-1999.
28. Gysin S, Salt M, Young A, McCormick F, (2011) Therapeutic strategies for targeting ras proteins. Genes Cancer 2: 359-372.
29. Meier F, Schittek B, Busch S, Garbe C, Smalley K, et al. (2005) The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10: 2986-3001.
30. Matsuo Y, Sawai H, Ochi N, Yasuda A, Takahashi H, et al. (2009) Interleukin-1alpha secreted by pancreatic cancer cells promotes angiogenesis and its therapeutic implications. J Surg Res 153: 274-281.
31. Chirivi RG, Garofalo A, Padura IM, Mantovani A, Giavazzi R, (1993) Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Res 53: 5051-5054.
32. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, et al. (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23: 269-284.
33. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
34. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, et al. (2003) Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 161: 817-826.